Getting treatment for your patients doesn’t have to be difficult

Looking for Samples?

With the EUFLEXXA Sample Program you can request samples by:
Asking A Representative
Requesting A
Representative
registering
Online

All orders are processed within 1 business day after enrollment.

Need Ordering Support?

EUFLEXXA can be ordered through any of these authorized distributors.
Contact your local sales representative for more information.
Request a Rep Now

Resources &
Coverage

Find helpful resources and coverage to
support your practice and your patients.

Get Support

Efficacy

Discover how EUFLEXXA performed
across three robust clinical trials.

Explore the Results
  1. Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

 

You have selected to go to the
healthcare professional website.

Are you a US healthcare professional?

Yes No

Get in contact with a EUFLEXXA representative

Fill out the form below and a representative will get in touch with you shortly.

Email
Address
I would like:

By clicking, I agree to the Terms and Conditions regarding the use of my information.

By providing the information requested above, I authorize Ferring to enter the information I have provided into a database. I agree that Ferring, its agents, subcontractors, affiliates, or third parties under contract with them may contact me from time to time by telephone, mail, or email to provide information about products or services that may be of interest to me. I understand that the information will be treated confidentially and will be accessed only by authorzed personnel or third parties under contract with Ferring or its affiliates.

I have a right of access and verification to my personal information. I also have a right to opt out of the database at any time. Subject to the above, unless authorized by me, my personal information will not be sold or transferred to third parties, other than in the event of Ferring or its affiliates being sold. If you no longer wish to receive such communications from Ferring, you may “opt out” at any time by calling Ferring at 1-888-FERRING, Monday through Friday 8AM to 7PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

This website may contain links to, or be accessed from links on, other worldwide websites. Ferring does not have responsibility for or control the contents, availability, operation or performance of other websites to which this website may be linked or from which this website may be accessed.

Ferring makes no representation regarding the content of any other websites which you may access from this website.

Ok Cancel